Cardiostimulatory effects of oxyfedrine, DMPP and sympathomimetics in relation to their 3H-noradrenaline-releasing properties.
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000818:Animals; D001337:Autonomic Agents / Q000494:pharmacology; D002395:Catecholamines / Q000494:pharmacology*; D004809:Ephedrine / Q000494:pharmacology*; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009206:Myocardium; D009638:Norepinephrine / Q000378:metabolism / Q000494:pharmacology*; D010477:Perfusion; D010879:Piperazines / Q000494:pharmacology*; D011427:Propiophenones / Q000494:pharmacology*; D011955:Receptors, Drug; D013268:Stimulation, Chemical; D013566:Sympathomimetics / Q000494:pharmacology*; D013618:Tachyphylaxis; D014316:Tritium
D000318:Adrenergic beta-Agonists; D001337:Autonomic Agents; D002395:Catecholamines; D010879:Piperazines; D011427:Propiophenones; D011955:Receptors, Drug; D013566:Sympathomimetics; D014316:Tritium; D004809:Ephedrine; D009638:Norepinephrine; D004837:Epinephrine